The global psoriasis drugs market size is expected to be valued at USD 21.11 billion by 2022, as per a new report by Radiant Insights, Inc., experiencing a CAGR of 9.4% during the forecast period. Rising disease awareness, increasing number of reimbursement strategies for biologics, and advanced diagnostic and technological tools are likely to increase the adoption of psoriasis therapeutics.
Additionally, expanding base of patients suffering from psoriasis is anticipated to fuel growth prospects. The exact causative factors for psoriasis are undetermined; however, certain genetic and environmental factors may trigger the disease onset. Most available treatments aim to decelerate disease progression by stopping hyperproliferation of keratinocyte.
Psoriasis can be classified into five types: plaque, guttate, inverse, pustular, and erythrodermic. The types vary in terms of site of disease and characterization of lesions. Erythrodermic psoriasis is the rarest and plaque psoriasis is the most prevalent type affecting patients all over the world.
Download Free Sample Report @ https://www.radiantinsights.com/research/psoriasis-drugs-market/request-sample
Incidence rate of psoriasis has witnessed a gradual rise over the years across various geographical locations. This increase can be attributed to genetic and environmental triggers as well as lifestyle changes. Rise in prevalence rates could also be associated with declining response or developing resistance to therapies for disease control.
Further key findings from the report suggest:
• Tumor Necrosis Factor-inhibitors dominated the market in 2016 owing to its higher usage by healthcare practitioners and easy availability
• TNF-inhibitors are likely to lose market shares over the forecast period due to increasing preference for IL-inhibitor therapy to conventional TNF-inhibitors
• Interleukin-inhibitors is expected to register a lucrative CAGR of over 21.0% during the forecast period owing to improved safety and efficacy profiles of Interleukin-inhibiting drugs
• The U.S is the dominant region in the psoriasis market in terms of revenue in 2016 due to increasing number of patients seeking treatment and presence of well-established healthcare services
• Japan is expected to be the fastest growing region during the same period due to growing awareness about the disease among the populace
• Some of the key players in this industry are AbbVie Inc.; Amgen Inc.; Johnson & Johnson; Novartis AG; Eli Lilly & Company; AstraZeneca; Celgene Corporation; UCB; and Merck.
Browse Full Research Report with TOC @ https://www.radiantinsights.com/research/psoriasis-drugs-market
Table of Contents
Chapter 1 Research Methodology
1.1 Information Procurement
1.2 Information or Data Analysis
1.2.1 Market Formulation & Validation
Chapter 2 Executive Summary
Chapter 3 Disease Primer and Epidemiology
3.1 Disease Primer
3.1.1 Types:
3.1.1.1 Plaque Psoriasis
3.1.1.2 Guttate Psoriasis
3.1.1.3 Inverse Psoriasis
3.1.1.4 Pustular Psoriasis
3.1.1.5 Erythrodermic Psoriasis
3.1.2 Complications
3.2 Epidemiology by Indications
3.3 Current Prevalence for Seven Major Markets (U.S., Japan, EU5)
3.4 Current Incidence for Seven Major Markets (U.S., Japan, EU5)
3.5 Forecast Prevalence and Incidence (U.S., Japan, EU5)
Browse More Report in Pharmaceutical Industry:
1) Clinical Data Analytics Market – https://www.radiantinsights.com/research/global-clinical-data-analytics-market-research-report-2019
2 Healthcare Packaging Market – https://healthcareandpharma.blogspot.com/2019/02/global-healthcare-packaging-market-2016-2025.html
3) Scar Dressing Market – https://healthcareindustrydata.blogspot.com/2019/02/global-scar-dressing-market-size-share.html
Media Contact
Company Name: Radiant Insights, Inc.
Contact Person: Michelle Thoras, Corporate Sales Specialist – USA
Email: Send Email
Phone: (415) 349-0054, Toll Free: 1-888-928-9744
Address:201 Spear Street 1100, Suite 3036
City: San Francisco
State: CA
Country: United States
Website: www.radiantinsights.com/research/psoriasis-drugs-market